Wnt signaling in osteosarcoma

Advances in Experimental Medicine and Biology

Volumn 804, Issue , 2014, Pages 33-45

  Lin, Carol H ^a,b   Ji, Tao ^b,c   Chen, Cheng Fong ^b,d   Hoang, Bang H ^b  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PEKING UNIVERSITY   (China)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Dickkopf; Frizzled related proteins; Osteosarcoma; Wnt; Wnt inhibitory protein; catenin

Indexed keywords

BETA CATENIN; CELECOXIB; DICKKOPF 1 PROTEIN; FRIZZLED PROTEIN; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SCLEROSTIN; WNT PROTEIN; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER INHIBITION; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; HUMAN; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH; ADOLESCENT; BONE TUMOR; CHILD; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; REVIEW;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BETA CATENIN; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; FRIZZLED RECEPTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; OSTEOSARCOMA; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84907170839     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-04843-7_2     Document Type: Article

References (92)

1. Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115(7): 1531-1543.
2. Bacci G et al (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18(24): 4016-4027.
3. Mialou V et al (2005) Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome-the French pediatric experience. Cancer 104(5): 1100-1109.
4. Hayden JB, Hoang BH (2006) Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 37(1): 1-7.
5. Lewis IJ et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99(2): 112-128.
6. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6): 1192-1205.
7. Nusse R, Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31(1): 99-109.
8. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434(7035): 843-850.
9. Lustig B, Behrens J (2003) The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129(4): 199-221.
10. van Amerongen R, Mikels A, Nusse R (2008) Alternative wnt signaling is initiated by distinct receptors. Sci Signal 1(35): re9.
11. Waltzer L, Bienz M (1999) The control of beta-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev 18(2): 231-246.
12. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14(15): 1837-1851.
13. Polakis P (1999) The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9(1): 15-21.
14. Behrens J (2000) Control of beta-catenin signaling in tumor development. Ann N Y Acad Sci 910: 21-33, discussion 33-5.
15. Moon RT (2005) Wnt/beta-catenin pathway. Sci STKE 2005(271): cm1.
16. Yeh JR, Peterson RT (2009) Novel Wnt antagonists target porcupine and Axin. Nat Chem Biol 5(2): 74-75.
17. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87(2): 159-170.
18. Thomas DM (2010) Wnts, bone and cancer. J Pathol 220(1): 1-4.
19. McQueen P et al (2011) The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11(8): 1223-1232.
20. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17(1): 9-26.
21. Jamieson C, Sharma M, Henderson BR (2012) Wnt signaling from membrane to nucleus: beta-catenin caught in a loop. Int J Biochem Cell Biol 44(6): 847-850.
22. Luu HH et al (2004) Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 4(8): 653-671.
23. Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810.
24. Zi X et al (2005) Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65(21): 9762-9770.
25. Mohinta S et al (2007) Wnt pathway and breast cancer. Front Biosci 12: 4020-4033.
26. Tomita H et al (2007) Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res 67(9): 4079-4087.
27. Najdi R, Holcombe RF, Waterman ML (2011) Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog 10: 5.
28. Larue L, Delmas V (2006) The WNT/Beta-catenin pathway in melanoma. Front Biosci 11: 733-742.
29. Takahashi-Yanaga F, Sasaguri T (2007) The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 104(4): 293-302.
30. Nusse R (2012) Wnt signaling. Cold Spring Harb Perspect Biol 4(5).
31. Korinek V et al (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 275(5307): 1784-1787.
32. Morin PJ et al (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275(5307): 1787-1790.
33. Hoang BH (2012) Wnt, osteosarcoma, and future therapy. J Am Acad Orthop Surg 20(1): 58-59.
34. Hoang BH et al (2004) Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109(1): 106-111.
35. Guo Y et al (2008) Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 466(9): 2039-2045.
36. Guo Y et al (2007) Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25(7): 964-971.
37. Hsieh SY et al (2004) Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 23(57): 9183-9189.
38. Veeck J, Dahl E (2012) Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta 1825(1): 18-28.
39. Hoang BH et al (2004) Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64(8): 2734-2739.
40. Lin CH et al (2013) Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma 2013: 147541.
41. Hoang B et al (1996) Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem 271(42): 26131-26137.
42. Leyns L et al (1997) Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88(6): 747-756.
43. Guo Y et al (2008) Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res 68(9): 3350-3360.
44. Patane S et al (2006) MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66(9): 4750-4757.
45. Mandal D et al (2007) Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 386(1-2): 131-138.
46. DeAlmeida VI et al (2007) The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 67(11): 5371-5379.
47. Wissmann C et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201(2): 204-212.
48. Rubin EM et al (2010) Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9(3): 731-741.
49. Hsieh JC et al (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398(6726): 431-436.
50. Lin YC et al (2006) Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun 341(2): 635-640.
51. Mazieres J et al (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64(14): 4717-4720.
52. Ai L et al (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27(7): 1341-1348.
53. Taniguchi H et al (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53): 7946-7952.
54. Lee BB et al (2009) Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15(19): 6185-6191.
55. Kansara M et al (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119(4): 837-851.
56. Chen B et al (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5(2): 100-107.
57. Park CH et al (2005) The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 579(13): 2965-2971.
58. Hallett RM et al (2012) Small molecule antagonists of the Wnt/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One 7(3): e33976.
59. Leow PC et al (2010) Antitumor activity of natural compounds, curcumin and p KF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs 28(6): 766-782.
60. Liao AT et al (2007) A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet Comp Oncol 5(3): 177-196.
61. McCleese JK et al (2009) The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 125(12): 2792-2801.
62. Grandy D et al (2009) Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284(24): 16256-16263.
63. Li X et al (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20): 19883-19887.
64. Holdsworth G et al (2012) Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. J Biol Chem 287(32): 26464-26477.
65. Lewiecki EM (2011) Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med 12(65): 263-273.
66. Lewiecki EM (2011) Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 11(1): 117-127.
67. Cai Y et al (2010) Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220(1): 24-33.
68. Goentoro L, Kirschner MW (2009) Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell 36(5): 872-884.
69. Oishi I et al (2003) The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8(7): 645-654.
70. Kohn AD, Moon RT (2005) Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 38(3-4): 439-446.
71. Semenov MV et al (2007) SnapShot: noncanonical Wnt signaling pathways. Cell 131(7): 1378.
72. Ishitani T et al (2003) The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23(1): 131-139.
73. Dejmek J et al (2006) Wnt-5a/Ca2 +-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells. Mol Cell Biol 26(16): 6024-6036.
74. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 5(3): 367-377.
75. Wang Y, Nathans J (2007) Tissue/planar cell polarity in vertebrates: new insights and new questions. Development 134(4): 647-658.
76. Seifert JR, Mlodzik M (2007) Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 8(2): 126-138.
77. Enomoto M et al (2009) Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28(36): 3197-3208.
78. Dravid G et al (2005) Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells 23(10): 1489-1501.
79. Fuchs E, Tumbar T, Guasch G (2004) Socializing with the neighbors: stem cells and their niche. Cell 116(6): 769-778.
80. Zhou P et al (1995) Lymphoid enhancer factor 1 directs hair follicle patterning and epithelial cell fate. Genes Dev 9(6): 700-713.
81. Tirino V et al (2011) Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25(6): 2022-2030.
82. Wang L et al (2011) Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128(2): 294-303.
83. Barker N, Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5(12): 997-1014.
84. Luo J et al (2007) Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87(2): 97-103.
85. Moon RT et al (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5(9): 691-701.
86. Wei W et al (2009) Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 8: 76.
87. You L et al (2004) An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64(15): 5385-5389.
88. Shih IM et al (2000) The beta-catenin binding domain of adenomatous polyposis coli is suffi-cient for tumor suppression. Cancer Res 60(6): 1671-1676.
89. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4): 252-266.
90. Chan TA (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3(3): 166-174.
91. Xia JJ et al (2010) Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res 38(4): 1294-1304.
92. Takahashi-Yanaga F, Kahn M (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16(12): 3153-3162.